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The majority of T cells present in the bone marrow (BM) represent an activated/memory 
phenotype and most of these, if not all, are circulating T cells. Their lodging in the BM 
keeps them activated, turning the BM microenvironment into a “memory reservoir.” This 
article will focus on how T cell activation in the BM results in both direct and indirect 
effects on the hematopoiesis. The hematopoietic stem cell niche will be presented, with 
its main components and organization, along with the role played by T lymphocytes 
in basal and pathologic conditions and their effect on the bone remodeling process. 
Also discussed herein will be how “normal” bone mass peak is achieved only in the 
presence of an intact adaptive immune system, with T and B cells playing critical roles 
in this process. Our main hypothesis is that the partnership between T cells and cells 
of the BM microenvironment orchestrates numerous processes regulating immunity, 
hematopoiesis, and bone remodeling.
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The presence of T cells inside the bone marrow (BM) cavity has been reported mostly for central 
memory T cells (Tcm). It is suggested that hematopoietic stem cells (HSCs) niches serve as “hubs” 
for optimal T cell maintenance, as T cells can survive in the absence of antigen, in an environment 
rich in interleukin-7 (IL-7) and IL-15 (1), and other mediators believed to be important to T cell 
memory maintenance (2). Naive T cells can also be primed, get activated, and develop into effector 
cells inside the BM. Altogether, the BM can be seen as a primary lymphoid organ, which supports 
primary and secondary T cell responses (3). However, in the BM, the hematopoietic and the bone 
remodeling systems share the same microenvironment, together with T cells, which come from the 
periphery. These three components are maintained in equilibrium under homeostatic conditions. 
Nonetheless, when T cells are activated, this equilibrium is disrupted, and the result depends on the 
class of T cell response and its impact on hematopoiesis and bone remodeling.
The next sections will describe and discuss the interactions of BM T cells with the hematopoietic 
and bone remodeling systems. The first section starts describing the development and organization 
of the BM hematopoietic microenvironment, discussing the perivascular and endosteal niches and 
their players. In the second section, the role of T cell on shaping hematopoiesis and the correlation 
between the class of the adaptive response and type of innate immunity stimulated by specific T cells 
is presented as a cooperative ensemble. In the third section, T cell influence on bone remodeling is 
described, as well as the T cell-mediated interactions occurring either in physiological conditions or 
in two bone pathologies (arthritis and cancer metastasis). The main molecular axis that controls bone 
remodeling, RANK–RANK-L–OPG, is shared with T and B cells, and is discussed as the molecular 
basis for functional interaction between the skeletal and the adaptive immune systems. Finally, in 
FiGUre 1 | schematic presentation of the bone marrow microenvironment under “homeostatic” conditions. As previously described by Lambertsen and 
Weiss (15), HSC area, which harbors hematopoietic stem cells and uncommitted progenitors, comprises both endosteal and subendosteal niches. Committed 
progenitors and differentiated cells are distributed in the central and perisinusoidal niches, respectively. Quiescent hematopoietic stem cells are in close association 
with endosteal osteoblasts and bone-lining cells. As HSCs exit quiescence to proliferative states, they migrate and colonize the subendosteal perivascular niche, 
interacting with both endothelial cells and pericytes. Subendosteal sinusoid-derived pericytes serve as source for new osteoprogenitors, which will differentiate into 
osteoblasts during bone remodeling (adapted from Journal of Cellular Biochemistry, 2014, Cordeiro-Spinetti et al. with permission from John Wiley & Sons).
2
Bonomo et al. T Cell Impact on Bone Marrow Niches
Frontiers in Immunology | www.frontiersin.org May 2016 | Volume 7 | Article 184
the fourth section, T cell activities on both hematopoietic and 
bone remodeling systems are presented and the ability of T cells 
to orchestrate both systems is discussed according to the class of 
the response.
HeMatopoietiC steM CeLL niCHe in 
tHe BM: CLose to tHe Bone sUrFaCe, 
not Far FroM tHe BLood VesseL
establishment of the HsC niche in the BM
During embryo development, first HSCs emerge in the blood 
islands in the extra-embryonic mesoderm of the yolk sac (4–6). 
Classified as a primitive population of HSCs; HSCs differentiate 
into nucleated erythrocytes and monocyte-like myeloid cells. In 
a second wave of hematopoiesis, termed definitive hematopoi-
etic, HSCs emerge from the intra-embryonic mesoderm of the 
para-aortic-splanchnopleura/aorta-gonad-mesonephros (AGM) 
region. These cells, but not those derived from the yolk sac, are 
capable of fully reconstituting the BM of a lethally irradiated 
adult animal for 6 months or longer, indicating their definitive 
properties (4–8).
After blood circulation is established in the embryo, HSCs 
from both the yolk sac and the AGM region migrate and colonize 
the fetal liver. The fetal liver microenvironment is responsible 
for expanding the numbers of HSCs and promoting full com-
mitment of the mesoderm-derived hematopoietic progenitors 
(9–13). Fetal liver HSC numbers progressively increase, prior to 
the migration of the hematopoietic system to the recently formed 
BM cavities. Once established in the BM cavity, most primitive 
hematopoietic progenitors and stem cells reside in the endosteal 
and subendosteal regions. Committed progenitors and differenti-
ated cells derived from stem cells will then occupy the central and 
perisinusoidal regions of the BM cavity, respectively (Figure 1) 
(14–18).
The BM vasculature is composed of a dense network of blood 
vessels widely spread within the cavity. Along the bone diaphy-
sis axis, the central artery carries in arterial blood to supply 
BM cells demand, while, in the same region, the central sinus 
carries out venous blood and differentiated hematopoietic cells 
into the blood circulation. Finer arteries and arterioles branch 
out from the central artery prior to reaching the endosteal 
surfaces, where they create a web-like structure to provide 
nutrients to the HSC niche (19–21). Conversely, sinusoidal 
blood venules cross the BM cavity and coalesce into wider veins 
as they drain into a central sinus. Approximately, one-fifth of 
all long-term HSCs in the BM, identified by the expression 
of CD150, c-Kit, and Sca-1, and absence of lineage markers, 
are found in close association with endosteal osteoblasts (18, 
22–32) The remaining 80% dwell in the abluminal surface of 
the subendosteal sinusoids, interacting with pericytes and 
endothelial cells, both contributing to HSC self-renewal (28, 
33–35). These data derived from different groups indicate that 
the niche formed by endosteal osteoblasts and the subendosteal 
sinusoidal perivascular cells coexist and are referred “quiescent 
niche” and “proliferative niche,” respectively. In vitro and in vivo 
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studies suggest that endosteal osteoblasts in the niche stimulate 
self-renewal and quiescence of the HSC (24, 29, 31, 32, 36, 37). 
Such that in transgenic animals, increased or decreased num-
bers of osteoblasts result in increased or decreased numbers 
of long-term HSC, respectively, without affecting any of the 
other hematopoietic lineages in the BM (24, 31, 32, 38). In situ 
observations show that most of the HSC population is concen-
trated in the trabecular bone zone, which also concentrates 
high numbers of osteoblasts, sinusoids, and CXCL12-positive 
pericyte-like cells (35, 39). In either case, HSCs are supported 
by highly expressing CXCL12-positive cells (40). The existence 
of the two niches remains controversial.
In the BM cavity, the microenvironment organization must 
match the hematopoietic system differentiation cascade, and each 
niche composition depends upon quality and number of specific 
types of stromal cell populations. Stromal cells comprise almost 
all non-hematopoietic cells found in the BM cavity  –  osteo-
blasts, endothelial cells, perivascular cells, mesenchymal cells, 
and nerve cells  –  which assemble in an organized network to 
physically and biologically properly support hematopoiesis 
(16, 18, 23, 24, 32, 41). Among all stromal cells, mesenchymal 
population represents around 90%, including pericytes, mesen-
chymal stem cells (MSCs) and progenitors, perivascular cells, 
non-perivascular reticular cells, adventitial cells, and all types 
of myofibroblasts.
adaptive immune Cells in the BM
Translating the spatial organization of niches in conjunction 
with hematopoietic differentiation, it is conceivable that blood 
cell production follows a radial pattern within the BM cavity, 
with most primitive cells residing close to the bone surface and 
differentiated cells exiting the BM cavity through a central venous 
sinus (15, 16) (Figure 1). A few differentiated hematopoietic cells 
leave the BM cavity, circulate in the peripheral blood, differentiate 
inside other organs as T cells in the thymus, and then return to 
the BM cavity, migrating to specific niches and playing significant 
roles as “stromal cells.” As such, T cells participate in a paracrine 
and juxtacrine signaling to contribute to hematopoiesis. B and T 
lymphocytes are among those cells with the ability to return to the 
BM after a quick trip to peripheral blood and lymphoid tissues. 
After BM cavity entering, memory B-lymphocytes, plasma cells, 
and T cells concentrate in the perivascular niche of subendosteal 
sinusoids (Figure  1). They will dwell in close association with 
CXCL12 highly producing cells, from where they produce and 
secrete cytokines to help maintain hematopoiesis homeostasis as 
we know it (23, 42–46).
Recirculating memory B-lymphocytes and active plasma cells 
secrete considerable levels of IL-6 and TGF-β, contributing to 
a myelopoietic balance (45, 46). CD4+ T cells express CXCR4, 
which promotes their migration and colonization close to 
CXCL12 highly producing subendosteal sinusoid perivascular 
cells. CXCR4 expressing T cells provide substantial assistance to 
differentiating B-lymphocytes and produce membrane bound 
and secreted cytokines that regulate myelopoiesis (42, 45, 46). 
Of note, recirculating B and T cells will colonize those niches 
identified as HSCs proliferative niche.
adipocytes in the BM
Among those cells composing the stromal population, BM 
adipocytes apparently present the potential to contribute to both 
local and systemic metabolism (47, 48). BM adipose tissue (MAT) 
accumulation occurs during aging and other clinical conditions, 
including osteoporosis, diabetes, and gonadal dysfunction (48, 49), 
and interventions, such as chemotherapy and radiation (47, 49).
Osteoblasts, hematopoietic-supporting reticular cells, and BM 
adipocytes derive from a common precursor, named BM MSC, 
also known as skeletal stem cell or stromal stem cell (47–52). 
Clinical and histomorphometric studies have shown a correla-
tion between MAT accumulation and decreased bone formation 
and increased bone loss (48), as hormones, corticoids, and local 
and peripheral factors might induce mesenchymal progenitors to 
follow the adipogenic differentiation path at the expense of the 
osteogenic one. Recent data, however, indicate that the hypoth-
esis of a direct impact of MAT accumulation on skeletal tissue 
balance disruption is controversial, as adipocytes in the BM may 
present distinctive phenotypes, resembling either brown or white 
adipocytes, with potential different interactions with the skeletal 
tissue (53, 54).
Marrow adipose tissue accumulation and bone loss during 
aging and other conditions is usually accompanied by a decrease 
in HSCs number and blood cells production (55–59). In humans, 
when MAT areas mature in the yellow BM, adipocytes become 
densely packed and leave no room for active hematopoiesis (48, 
60). In humans, yellow BM adipocytes appear at or right before 
birth, increasing up to the eighth week of age. Larger animals 
have more yellow BM as compared to smaller animals, which also 
extends farther into the bone cavities (60–63).
Adipocytes in the red BM do not become packed, but several 
findings implicate them as negative regulators of hematopoiesis. 
Adipocyte-derived soluble factors inhibit both B lymphopoiesis 
and granulopoiesis in vitro by blocking committed progenitors 
differentiation (64–67). When co-cultured with BM adipocytes, 
HSCs show reduced self-renewal capacity as compared to those 
co-cultured with other stromal cells (23, 68–71). In vivo, BM 
cavity areas rich in adipocytes most likely hold lower numbers of 
HSCs and short-term repopulating cells (72). Moreover, wild-type 
HSCs present enhanced repopulation ability when transplanted 
into animals with reduced numbers of BM adipocytes (73, 74). 
It was also observed that the balance between osteoblast and 
adipocyte differentiation influences hematopoietic recovery after 
irradiation. Hematopoietic precursor numbers increase when 
Runx2 expression peaks and PPAR gamma expression decreases, 
suggesting that osteogenesis but not adipogenesis supports 
hematopoiesis (73). All data published so far support a negative 
effect of BM adipocytes in hematopoiesis, even though further 
investigation is definitely necessary.
In pathological conditions, primary or metastatic tumor cells 
can grow in the BM. In respect of the niches of tumor cells in the 
BM, the role played by BM adipocytes is not clear yet. Apparently, 
BM adipocytes might secrete factors, which will modulate 
hematopoietic, immune, and tumor cells behavior in the niche. 
However, it is also very likely that the disruption in the osteoblast/
adipocyte differentiation balance results in a new combination of 
FiGUre 2 | t cells help normal hematopoiesis – (a) in the absence of t cells, or in the presence of non-activated t cells (not represented), immature 
progenitors cells, particularly of the myeloid lineage, accumulate in the bone marrow resulting in peripheral granulopenia. (B) When activated T cells 
are present, they can see antigen in several hematopoietic cells and release growth factors, in return. These cytokines can directly and indirectly affect maturation of 
myeloid progenitors. Also, T cell cytokines modulate the stroma, which in turn can modulate HSC maintenance and myeloid differentiation. The number of HSC is 
also higher than in the T-less environment (adapted from Journal of Cellular Biochemistry, 2014, Cordeiro Spinetti et al. with permission from John Wiley & Sons).
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stromal cells and formation of different categories of niches in 
the BM cavity.
t CeLL in HeMatopoiesis: 
orCHestratinG tHe  
peripHeraL deMand
t Cell Help Keeps “normal” 
Hematopoiesis in the BM
One of the first links between T lymphocytes and hematopoiesis 
emerges during development, and the relationship persists 
throughout life (75, 76). In vitro, it was shown that T cells could 
instruct splenic hematopoiesis in response to syngeneic stimu-
lation (77). Also, patients receiving T cell depleted allogeneic 
BM transplantation have higher rates of graft failure (78, 79). 
Nonetheless, when CD3+ cells were co-administered with 
allogeneic BM stem cells, improvement and optimization of 
hematopoietic cells engraftment is observed (80).
Using athymic mice, our data suggest that T cell interac-
tions with hematopoietic precursor populations maintain 
hematopoiesis. These athymic mice exhibit granulocytopenia 
in the peripheral blood, as immature granulocytes accumulate 
in the BM (Figure 2A). Importantly, immature hematopoietic 
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cells in the BM have no intrinsic defect that prevents their 
differentiation, since in  vitro stimulation with growth factors 
induces their differentiation and maturation. Thymus graft or 
CD4+ T cells’ adoptive transfer, but not CD8+ T cells, rescues 
normal hematopoiesis and restores peripheral granulocytes 
counts. These CD4+ T lymphocytes present in the BM are pre-
dominantly activated and produce IL-4 and IFN-γ, even in the 
absence of any intentional external antigen stimulation (42, 81). 
However, if T cells are virgin, meaning they have yet to interact 
with their cognate antigen (as in TCR transgenic mice specific 
for an external antigen), peripheral granulopenia with accumu-
lation of myeloid blasts in the BM is observed (42). “Normal” 
hematopoiesis is restored, however, if T cells are activated with 
their cognate antigen (Figure 2B). This work demonstrates that, 
among its functions, T cell cross talk with hematopoiesis plays a 
critical role in “normal” hematopoiesis.
One critical demonstration of this relationship comes from 
studies with hyper IgM immunodeficiency patients. These patients 
have a mutation in the CD40L gene, and their activated T cells 
do not assist B cells and macrophages in their activities, even in 
the presence of cognate antigen (82–84). However, these patients 
are also granulopenic, suggesting that CD40L is also important 
for hematopoiesis. In fact, CD40L engagement induces the pro-
duction of Flt3L by different cell types and thrombopoietin by 
BM stromal cells (85). Moreover, human CD34+ hematopoietic 
progenitor cell are CD40 positive and when CD40L binds to it, 
proliferation and myeloid differentiation take place, mainly on 
the dendritic cell (DC) pathway (86).
BM In Situ signaling and delivery of 
Cytokines: t Cells Bring the news
Studies on hematopoietic cells from the BM and the spleen of 
mice with diverse T helper cell polarization profiles provided 
clues on how T cells influence normal hematopoiesis. In mice 
with targeted deletion of STAT-4, which are biased to the Th2 
 phenotype, the number and cycling status of hematopoietic cells 
are significantly decreased compared to wild-type mice. By con-
trast, STAT-6 knockout mice, which are biased to Th1 response, 
demonstrate increased numbers of progenitors and cycling cells. 
This phenomenon is attributed to oncostatin M (OSM) secreted 
by Th1 T cells, since treatment of STAT-4-deficient mice with 
OSM recovers the number of cycling progenitors in the BM (87). 
From these observations, it becomes clear that activated BM T 
cells play an important role in hematopoiesis.
Further examples of T cells regulating hematopoiesis abound. 
For example Rådinger and colleagues (88, 89) reported that 
CD8+ T lymphocytes have a regulatory role in the control of 
eosinopoiesis in the BM. Transgenic mice overexpressing IL-5 in 
CD3+ cells and deficient in CD8+ cells show a significant decrease 
in BM eosinophils in steady state, what is not observed in the 
partner knockout mice to CD4+. In addition, adoptive transfer of 
naive CD8 T lymphocytes into immunodeficient mice (SCID-bg) 
restores normal levels of eosinophils in the BM. By contrast, in 
airway allergen challenge both T CD4 and CD8 subsets seem to 
be important in BM and bronchoalveolar lavage (BAL) eosino-
philia (88, 89). Another example of hematopoiesis regulation by 
T cells comes from adoptive transfer of activated antigen-specific 
CD8 T lymphocytes, leading to increased numbers of multipo-
tent and committed hematopoietic progenitor cells, especially 
myeloid lineage. These CD8 T cells secrete IFN-γ, which in turn 
acts on BM mesenchymal stromal cells, inducing these cells to 
release hematopoietic cytokines, especially IL-6. IL-6 modulates 
the expression of transcription factors essential to myeloid com-
mitment and promotes accumulation of myeloid cells in the 
periphery (90).
Another molecule that implicates T lymphocytes in hemat-
opoiesis is granulocyte macrophage colony-stimulating factor 
(GM-CSF). GM-CSF is a hematopoietic growth factor that 
stimulates proliferation of myeloid progenitor cells. It induces 
survival and activation of mature myeloid cells, and has a pro-
inflammatory role in different diseases (91, 92). Interestingly, 
the hematopoietic system of GM-CSF knockout mice is normal 
(93). However, these mice when infected with Mycobacterium 
avium (94) or Listeria monocytogenes (95) have severe depletion 
of BM hematopoietic cell numbers, a deficient inflammatory 
response and are unable to increase their colony-forming cells in 
BM. This suggests that GM-CSF is essential for a hematopoietic 
response emergency, but not required for normal hematopoiesis. 
Interestingly, Th1 and Th17 lymphocytes are able to produce and 
secrete GM-CSF when activated by different stimuli (96–99). 
Recently, GM-CSF producing T cells (Th-GM) were reported. 
Generation of GM-CSF+/IL3+ CD4 lymphocytes is mediated by 
IL-7/STAT-5 signaling, and Th-GMs do not express the transcrip-
tion factors T-bet and ROR-γt, suggesting that these cells belong 
to a distinct subset of Th cells (100, 101).
The effects of IL-17 in hematopoiesis appear to be largely 
indirect through the induction of cytokine secretion, includ-
ing GM-CSF, G-CSF, SCF, NO, IL-6, prostaglandins, and other 
chemokines (102–104). BM stromal cells are the main target 
of IL-17 as stromal and MSCs, express a high level of IL-17RA 
(105, 106).
treg inhibits differentiation and 
preserves the HsC pool
Recently, Treg lymphocytes involvement in hematopoiesis was 
investigated. The frequency of FoxP3 Treg cells in CD4 T cells is 
higher in the BM (around 20%) than that in the spleen and lymph 
nodes (10–15%) (107, 108). Treg cells suppress the function of 
CD4 and CD8 T cells. In a murine model of allogeneic hemat-
opoietic stem cell transplantation (HSCT) into non-irradiated 
recipients, Tregs co-localized with HSCTs and accumulated 
close to endosteum surface in the calvaria and trabecular BM. 
When Treg cells are depleted, a 70% reduction in the number 
of surviving donor cells, with concomitant increase in levels of 
TNF-α and IL-4 producing CD4+FoxP3− and CD8+ T BM cells 
is observed. These data suggest that Tregs provide an immune 
privilege mechanism that enables transplanted allo-HSPCs to 
escape allogeneic rejection in the BM (107). However, using a 
direct approach, Urbieta and colleagues (109) demonstrated that 
active Tregs are able to prevent the differentiation of IL-3/SCF 
colony-forming units (CFU) progenitor cells in  vitro and this 
inhibition depends upon T cell antigen recognition and TGF-β, 
but not on FasL and perforin. Moreover, in syngeneic HSCT, Treg 
depletion either in host mice or in donor cell population increases 
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splenic CFU-IL3 after transplantation indicating that donor and 
host Tregs can modulate hematopoiesis. In line with these results, 
addition of Tregs to T-cell-depleted transplants diminishes 
splenic and BM-derived CFU and peripheral neutrophil counts 
(109). It seems that Tregs indeed protect immature progenitors 
from differentiating and, most probably, help to keep the stem 
cell pool, although this deserves a more detailed investigation.
peripheral demand and Central 
Hematopoiesis Holding Hands
During infections and inflammatory conditions, immune effec-
tor cells, especially neutrophils, are highly demanded and rapidly 
consumed in peripheral tissues. Although adaptive immune cells 
(T and B lymphocytes) respond to efficient antigen presentation 
with activation and proliferation, innate immune cells need 
to be replenished to maintain the progenitor cells pool. The 
hematopoietic response to this need is named demand-adapted 
hematopoiesis or emergency hematopoiesis.
T lymphocytes fit well with the definition of “messengers from 
the periphery to the BM” (Figure 2). The beauty of the system is 
that the pleiotropic effect of T cell interaction with multiple sys-
tems coordinates the immune response “class” in the adaptive as 
well as in the innate compartment. Th2 responses are the example 
prototype, with IL-4 being the master cytokine orchestrating the 
immune response. In the periphery, Th2 cells help B cells with a 
consequent switch in immunoglobulin class to IgE. In the BM, 
IL-4 induces mast cell differentiation. IgE has no function alone 
and works in pair with mast cells, made possible by the stimula-
tion of IgE production by B cells and mast cells differentiation 
from BM progenitors, in a coordinated manner. Similar to this, 
Th1 responses induce IgG2a class switch in B cells and activate 
macrophages through IFN-γ, which inhibits osteoclast (OC) 
differentiation favoring the monocyte differentiation pathway 
(110). IgG2a is a good opsonin to which macrophages have high-
affinity receptors. Th1 activity in the BM increases differentiation 
of monocytes, which have high-affinity receptors for IgG2a, and 
the immunoglobulin isotype is also stimulated by Th1 cells. In 
parallel to what was described above for Th2 cells, Th1 cells coor-
dinate hematopoietic activity with adaptive immunity, with the 
immunoglobulin class switch improving innate immunity. Less 
obvious is the Th17 response, which is closely related to indirect 
actions, but signals on epithelial and stromal cells licensing those 
for production of cytokines, which will stimulate granulopoiesis 
and neutrophil migration to the damaged tissue. These cells are 
short lived and highly demanded, especially in the first phase of 
the response, needing to be replaced and produced in accelerated 
rates. This can be achieved after the Th17-specific cell engages 
its TCR on the surface of an antigen-presenting cell (APC) in 
the BM (42, 111, 112). Th17 cells secrete IL-17 and GM-CSF and 
stimulate BM stromal cells to produce G-CSF, modifying hemat-
opoiesis based on antigen-specific peripheral demand.
There are still many points to be considered and investigated 
in the relationship between T lymphocytes and the hematopoietic 
system. However, the data gathered here provide strong evidence 
that this is not a simple and static relationship; it is modulated 
according to BM microenvironment, as well as by changes in the 
external environment sensed with the help of activated T cells.
t CeLL and tHe Bone: reGULatinG 
tHe Bone reModeLinG systeM
Bone remodeling: the players
The skeletal system renews itself completely every 18  years, 
indicating its dynamic metabolism. Subendosteal perivascular 
cells serve as source for new osteoprogenitors in the BM cavity 
(68, 113, 114). As bone remodels, several factors released from 
the matrix after OC-mediated bone resorption will recruit bone-
lining cells to become activate osteoblasts (113, 115). Osteoblasts 
will then deposit new bone matrix and further mineralize it. 
During bone deposition, a few osteoblasts get trapped in the 
matrix and become fully differentiated osteogenic cells, turning 
into osteocytes (113, 115).
Osteoclasts, on the other hand, derive from the hematopoietic 
lineage. OCs are bone resident cells involved in physiological and 
pathological remodeling of bone tissue. Mature OCs are tartrate-
resistant acid phosphatase (TRAP), calcitonin receptor, cathepsin 
K, αβ3-integrin, and adenosine triphosphate-dependent proton 
pump subunits positive, multinucleated giant cells that are gener-
ated from the fusion of precursors derived from the monocyte/
macrophage lineage (116). Mature OCs polarize and adhere 
to the bone matrix, acidify the bone surface, release osteolytic 
enzymes, and resorb bone. Two factors appear as crucial for OC 
differentiation: macrophage colony-stimulating factor (M-CSF), 
which induces monocyte differentiation, and RANKL, which is 
essential for stimulating pre-OC differentiation and its merge into 
multinucleated cells. Both factors are believed to derive mainly 
from osteoprogenitor cells and pre-osteoblast. Osteoblasts, on 
the other hand, produce and secrete osteoprotegerin (OPG) that 
is a RANK decoy receptor and inhibits OC formation and bone 
resorption (116).
Under physiological conditions, the balance between bone 
formation and resorption is finely tuned and can be disrupted 
under non-homeostatic conditions (Figure 3A).
ranK–ranKL–opG axis: Linking the 
immune and skeletal system
RANKL (also known as ODF, TRANCE, OPGL, and TNFSF11) 
and its receptor RANK (also known as TRANCE-R and 
TNFRSF11A) central players in bone metabolism (117) were first 
described as molecules expressed in T cells and DCs. OPG, the 
soluble receptor/antagonist for RANKL, initially characterized 
as an inhibitor factor of OC development and bone resorption, 
expressed by osteoblasts (116, 118), and B cells (119, 120), has 
also been described as a crucial regulator of B cell maturation 
and development of antibody responses (121). In fact, the RANK/
RANKL system also controls lymph node organogenesis and 
development of thymic medullary epithelial cells and lympho-
cytes (122–124). The RANK–RANKL–OPG axis also has impor-
tant functions in other systems, such as the lactating breast, and 
in the thermo-regulatory system (125). Regulation of tumor cell 
migration to the bone as well as primary mammary tumor growth 
had also been reported and relate to physiological activities of 
these molecules (126).
The role of the adaptive immune system in what is known as 
the equilibrium between bone consumption and deposition in 
FiGUre 3 | adaptive immunity participates in physiological bone remodeling – (a) bone remodeling relies on osteoclasts (oC), which in physiological 
situations differentiate from oC precursors of the monocytic lineage after signaling through ranK in its surface and ranKL produced by 
osteoprogenitor cells. As the bone is resorbed, growth factors and other molecules stored in the extracellular matrix are released, including TGF-β that stimulates 
osteoblastogenesis from MSC, which reside in the perivascular niche (as in the representation) or in the endosteal niche (not represented). As a consequence, new 
osteoblasts are formed resulting in bone formation. OPG, a decoy receptor for RANKL, is produced by osteoblasts and participate modulating the bone remodeling 
system. (B) When activated T cells are present, they activate B cells in a CD40–CD40L-dependent manner with OPG production in large quantities by B cells. This 
leads to bone accumulation as the RANK–RANKL axis is disrupted by the high amounts of OPG produced by B cells. This is what defines the “normal” bone mass 
in physiological situation, in SPF condition. Dashed lines represent cellular differentiation; filled line represents cytokine action.
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healthy animals was addressed by Li et  al. (119). They showed 
that acquisition of normal bone mass depends on the presence 
of OPG produced by mature activated B cells. However, in the 
absence of T cells, B cells do not produce OPG and bone remod-
eling is unbalanced toward bone consumption due to lack of the 
inhibitory OPG–RANKL loop. Moreover, OPG production by 
B cells was dependent upon CD40L from activated T cells, show-
ing that T–B interaction is required for “normal” bone density 
maintenance (Figure 3B).
Evidence related to hormonal (estrogen) regulation of TNF-α 
production by T cells have also been published, and data link 
adaptive immunity to bone activity (127). However, the results 
vary depending on the model used (128). In the presence of 
B cells, but in the absence of T cells, bone mass decreases after 
ovariectomy, in accordance to Li et al. (119). In this case, B cells 
are present, but are not activated by T cells. However, if both, 
B and T cells are absent, as in RAG-deficient mice, bone mass 
increases after ovariectomy making any conclusion about the role 
of estrogen in regulation of T cell activity over the bone difficult 
at the present moment.
Apart from hormones, another important evidence of T cell 
participation in physiological bone remodeling comes from 
studies in germ-free (GF) mice (127, 129). These animals have 
lower numbers of T cells in the BM and these are not activated. 
Also, GF mice have low frequency of OCs and are osteopetrotic. 
Coincidentally, colonization with commensal microbiota reverses 
the osteopetrotic phenotype and restores normal numbers of 
activated T cells, as well as of OC precursors (130) These data are 
in accordance with the view that in steady-state healthy condi-
tions, recognition of antigen by T cells tunes the bone remodeling 
system.
T-cell-derived RANKL can contribute to bone loss in some 
pathological conditions, as it was first proposed by Kong and 
colleagues in a model of inflammatory bone disease (131). Later 
studies showing reversal of RANKL-dependent osteopetrosis by 
hyper-expression of RANKL in T and B cells (132) reinforced 
the interplay between adaptive immune cell-derived RANKL and 
bone metabolism. On the other hand, Sato et al. better described 
the involvement of T-cell-derived IL-17A and interaction with 
RANKL in synoviocyte and macrophages in the inflamed joint 
(133, 134).
Generally, the cross talk between both systems has been 
studied in models of arthritis, in which the action of T cells in an 
inflamed joint stimulates osteoclastogenesis and bone resorption 
through the indirect action of T-cell-derived IL-17A and RANKL 
(134–137). However, in the arthritis models, T cells reach the 
bone through the articular cavity after an inflammatory injury, 
which destroys the cartilage and exposes the periosteal bone 
surface.
In contrast to these mechanisms observed in arthritis, in other 
conditions, the T cells normally present inside the BM and in 
contact with the bone might contribute to pathological bone 
remodeling. In fact, we have recently shown that RANKL produc-
tion by tumor-primed BM CD4+ T cells induces pre-metastatic 
osteolytic bone disease that licenses metastatic colonization 
(138). We reached this conclusion by showing that the 4T1 breast 
tumor induces production of pro-osteoclastogenic cytokines, 
IL-17F, and RANKL by BM CD4+ T cells, leading to OC forma-
tion and activation in vitro and in vivo. Surprisingly, osteolytic 
disease was observed even before tumor cells colonized the bone 
and was induced by T cell transfer, showing that T cells prepare 
the metastatic niche for further establishment of tumor cells 
FiGUre 4 | t-cell-derived ranKL prepares the bone pre-metastatic niche. (a) After responding T cells meet tumor antigen and get activated, they migrate to 
the bone marrow where, after encountering antigen, they release cytokines. In the case of a metastatic tumor, responding T cells produce IL-17 and RANKL. 
Although IL-17F from T cells can indirectly influences osteoclastogenesis, T-cell-derived RANKL is the central cytokine stimulating osteoclastogenesis and bone 
consumption resulting in pre-metastatic niche organization with growth factor release from the resorbed matrix. (B) The growth factor-rich environment will nourishes 
the arriving tumor cells allowing metastatic colonization. In the absence of T-cell-derived RANKL, metastatization into the bone does not take place.
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(Figure 4A). Thus, the T cell mediated pre-metastatic osteolytic 
disease adds an extra step to the vicious cycle hypothesis, which 
established that bone colonization by tumor cells culminate in the 
release of growth factors from the bone matrix as a consequence 
of OC activity (Figure 4B) (139, 140).
osteoclasts and dendritic Cells: 
Modulators of the Bone remodeling Gear
Interactions between monocytes/macrophages and OCs has 
long been studied and was appreciated in the pioneering work of 
Horton et al. in the early 1970s (141). The set of soluble factors 
secreted from antigen-stimulated peripheral blood mononuclear 
cells was initially described as an “OC-activating factor,” which 
subsequently was identified as predominantly interleukin-1 
(IL-1) and TNF (142). In addition, numerous macrophage-
derived cytokines influence OC differentiation and/or function, 
such as M-CSF, which are essential for the development and 
survival of the monocyte/macrophage lineage as well as OC 
differentiation (136).
One important cell type also derived from monocytic progeni-
tors and precursors in the BM is the DC, the most potent APC, 
responsible for activating naive T cells, and orchestrating the 
immune responses (143). Since DCs are derived from the same 
monocyte/macrophage OC precursor lineage, it is not surprising 
that splenic immature DCs can be developed into OCs (OC–DC), 
when cultured with osteoclastogenic factors M-CSF and RANKL 
(144–146).
Accumulated evidence indicates that mature OCs can func-
tion as APCs to both CD4+ and CD8+ T cells in vitro. They express 
MHC I and II, CD80, CD86, CD40, IL-10, TGF-β, IL-6, and 
TNF-α, all molecules that act on T cell activation and class switch 
(147). It has been suggested that the monocyte population used 
to differentiate OCs carry contaminant DCs or monocyte them-
selves, which could explain the antigen-presenting capabilities of 
OCs. OCs can in fact be derived from immature DCs in vivo and 
in vitro (148–150), although the antigen-presenting capability of 
these OC–DCs had never been addressed.
Circulating DCs are normally recruited to inflamed tissues 
(149, 151) and IL-23-producing DCs play an indirect role in 
osteoclastogenesis by stimulating T cell expression of RANKL 
and IL-1, IL-6, IL-17, and TNF-α that augment the release 
of TRAP and cathepsin K by resident OCs (149). A still-open 
question is whether the same growth factors that control nor-
mal osteoclastogenesis are also involved in generating OCs in 
response to inflammation with potent DC activity. Participation 
of OC–DC in bone remodeling was suggested in Langerhans 
cell histiocytosis (LCH). LCH is a multi-symptom disease with 
associated bone resorption and granuloma formation, and soft 
tissue inflammatory lesions (152). Bone pathology appears to 
rely on DCs and monocytes, which produce high levels of IL-17A 
and induce DC–OC differentiation (150, 153). Also it was shown 
that DCs could induce osteolysis when transferred to regular or 
osteopetrotic mice (154). Osteolytic activity in vivo was inhibited 
with OPG and bisphosphonates, implying a role for RANKL in 
the pathogenic DC–OC pathway (154).
Since it was shown that DC can prime T cells inside the BM 
(155), it can be reasoned that a DC can acquire OC characteristics 
while keeping its antigen-presenting capabilities. If this is true, 
then DCs can work as messengers from the periphery to the BM 
where they maintain T cell activation/memory and interfere with 
bone metabolism, in addition to participating in hematopoiesis 
(Figure 5).
FinaL reMarKs: tUninG 
tHe BM MULtisysteM
The skeletal system provides vital functions, as mechanical 
structure, movement, protection, calcium storage, endocrine 
FiGUre 6 | t cell regulation of bone marrow environment. T cell participation in the BM environment promotes what we know as “normal hematopoiesis” and 
“normal bone mass.” In hematopoiesis, T cell release of hematopoietic cytokines after activation allows terminal differentiation of hematopoietic progenitors/
precursors, which will compose the “normal” peripheral pool. “Normal” bone density is also dependent on T cell activation, which in a normal state activates B cells 
to produce OPG, balancing bone resorption by OCs and mineral deposition by OBs. If T cells are highly activated or are turned into an osteoclastogenic phenotype, 
excessive bone resorption can lead to osteolytic disease. Moreover, some of the cytokines produced by T cells that can interfere with the bone remodeling system 
can also affect hematopoiesis, such as IL-17F.
FiGUre 5 | osteoclasts are optimal antigen-presenting cells when derived from dCs, but not from BM progenitors. Osteoclasts are usually derived from 
bone marrow progenitors or monocytic precursors (OC), but can also derive from dendritic cells under certain conditions (OC–DC). (a) Classical “constitutive” OC. 
OC are not good antigen presenters, cannot activate T cells, and do not maintain T cell activation in the BM. Thus, OCs do not contribute to T cell activation in the 
BM. (B) Activation induced OC–DC. Under the influence of RANKL among other cytokines, OC–DCs are induced. If OC–DCs are as good as fresh DCs in 
presenting antigen to T cells and if they provide IL-23, a positive loop will be built, which can amplify the osteoclastogenic potential of T cell stimulation. In this 
context, the bone-resorbing activity of both DC–OC and classical OC will result in decreased bone mass (represented by the light color of the matrix). Whether both 
OCs dwells in the same resorbing pit, or are segregated into separate subniches, as represented in B, is unknown.
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regulation, and support for the whole hematopoietic system. 
Blood cell production is a very finely controlled process, which 
depends upon stromal cells and their factors, and cell intrinsic 
conditions. In the BM cavity, HSCs and progenitors reside close 
to the bone surfaces, which suggests that the two systems are 
integrated.
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